4th Dermatology Drug Development Summit Europe

The renowned 4th Dermatology Drug Development Summit Europe returns as the definitive industry-led conference for all administration routes, for chemistry and non-clinical researchers, through to clinical drug developers and strategic decision makers. 

Bringing you fresh content covering Hidradenitis Suppurativa, Pachyonychia Congenita, Keratodermas and Neurofibromas as well as the latest advances in Atopic Dermatitis.

Equip your chemists with knowledge of chemical modifications to promote stability and mitigate the risk of off-target effects reducing toxicity. Debate optimal dosing strategies topical vs oral vs intravenous. Evaluate a range of current and future drug delivery methods and discuss important considerations when treating hyperkeratotic skin 

Whatever your role in the dermatology field, this summit is designed to equip you with the tools to tackle the next dermatology opportunity, progressing existing treatments and developing successful therapies for rarer dermatological diseases.

Prices:
Drug Developer Pricing Conference + 2 Workshops: EUR 3897.00,
Drug Developer Pricing Conference + 1 Workshop: EUR 3348.00,
Drug Developer Pricing Conference Only: EUR 2999.00,
Service Provider Pricing Conference + 2 Workshops: EUR 4697.00,
Service Provider Pricing Conference + 1 Workshop: EUR 4048.00,
Service Provider Pricing Conference Only: EUR 3399.00,
Academic and Research Institute Pricing Conference + 2 Workshops: EUR 3397.00,
Academic and Research Institute Pricing Conference + 1 Workshop: EUR 2898.00,
Academic and Research Institute Pricing Conference Only: EUR 2399.00

Speakers: Ayman Grada, Director - Medical Atopic Dermatitis and Dermatology Pipeline, Abbvie, Braham Shroot, Chief Scientific Officer, Palvella Therapeutics, Carlo Pincelli, Chief Medical Officer, PinCell, Edel O'Toole, Professor of Molecular Dermatology, Queen Mary University Of London, Harald Schnidar, Chief Executive Officer and President, Scarletred Holding Gmbh, Hyun Kim, Vice President and Head of Clinical Operations, AOBiome, Jane McGuffog, Vice President of Drug Discovery, BenevolentAI, Kim Domela Kjoller, Chief Executive Officer, UNION Therapeutics, Lars Rosendal, Vice President, Global Clinical Operations, LEO Pharma, Leo Holmgren, Chief Executive Officer, TIRmed, Liora Braiman-Wiksman, Chief Scientific Officer, Kamari Pharma, Melanie LaszczykLauer, Head of Stability and CMC, Amryt GmbH, Neal Walker, Chief Executive Officer, Alphyn Biologics, Primal Kaur, Vice President Global Development, Amgen Inc., Rajeev Chavda, Senior Expert - Global Medical, Galderma Laboratories, Sreekumar Pillai, Executive Director - Immunology Clinical Development, Eli Lilly, Thomas Hultsch, Vice President and Head of Translational Medicine, Leo Pharma Inc, William Hodder, Chief Executive Officer, NFlection Therapeutics Inc., Youb Chalabi, Director - Global Clinical Development and Immunology Medical, Biogen

Others Details

Brochure: https://go.evvnt.com/1544780-2?pid=6581